安科生物：公司自主研发的“AK2017注射液”临床试验进展顺利

Core Viewpoint - Anke Bio announced the smooth progress of its self-developed "AK2017 Injection" clinical trials, having completed the enrollment for Phase II trials and submitted a supplementary application for Phase III trials, which are expected to start in early next year [2] Group 1 - The company has successfully completed the enrollment for Phase II clinical trials of "AK2017 Injection" [2] - A supplementary application for Phase III clinical trials has been submitted [2] - The initiation of Phase III clinical trials is anticipated to begin in early next year [2]